These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 15915389)

  • 1. [Role of PAI-1 in gynaecological malignancies].
    Könsgen D; Mustea A; Lichtenegger W; Sehouli J
    Zentralbl Gynakol; 2005 Jun; 127(3):125-31. PubMed ID: 15915389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
    Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
    Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
    Bajou K
    Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
    Durand MK; Bødker JS; Christensen A; Dupont DM; Hansen M; Jensen JK; Kjelgaard S; Mathiasen L; Pedersen KE; Skeldal S; Wind T; Andreasen PA
    Thromb Haemost; 2004 Mar; 91(3):438-49. PubMed ID: 14983218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
    Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM
    Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
    Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A
    Oncogene; 2004 Sep; 23(41):6986-90. PubMed ID: 15286708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
    Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
    Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasminogen activator inhibitor "paradox" in cancer.
    Binder BR; Mihaly J
    Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
    Sprague LD; Mengele K; Schilling D; Geurts-Moespot A; Sweep FC; Stadler P; Schmitt M; Molls M
    Oncology; 2006; 71(3-4):282-91. PubMed ID: 17671400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitors.
    Gils A
    Verh K Acad Geneeskd Belg; 2006; 68(3):179-98. PubMed ID: 16796017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR; Church FC
    Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.